bluuebunny/crossref_metadata_2025 huggingface dataset:
Suppl Figure 1 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
Authors: Micel Lindsey N. , Tentler John J. , Tan Aik-Choon , Selby Heather M. , Brunkow Kelsey L. , Robertson Kelli M. , Davis S. Lindsey , Klauck Peter J. , Pitts Todd M. , Gangolli Esha , Fabrey Robyn , O'Connell Shawn M. , Vincent Patrick W. , Eckhardt S. Gail
Published: April 2023

Suppl Figure 1. Chemical structure and molecular data for TAK-733
Supplementary Figure Legend from Targeted Silencing of MLL5β Inhibits Tumor Growth and Promotes Gamma-Irradiation Sensitization in HPV16/18-Associated Cervical Cancers
Authors: Nin Dawn Sijin , Yew Chow Wenn , Tay Sun Kuie , Deng Lih-Wen
Published: April 2023

Figure legends for supplementary figures S1 and S2.
Supplementary Table 1 from Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy
Authors: Onstenk Wendy , Kraan Jaco , Mostert Bianca , Timmermans Mieke M. , Charehbili Ayoub , Smit Vincent T.H.B.M. , Kroep Judith R. , Nortier Johan W.R. , van de Ven Saskia , Heijns Joan B. , Kessels Lonneke W. , van Laarhoven Hanneke W.M. , Bos Monique M.E.M. , van de Velde Cornelis J.H. , Gratama Jan W. , Sieuwerts Anieta M. , Martens John W.M. , Foekens John A. , Sleijfer Stefan
Published: April 2023

Clinicopathological characteristics, CTC and CEC counts, and primary tumor EpCAM and MCAM staining specified per patient.
Supplementary Table 8 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Supplementary Table 8 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Supplementary Figure S5 from Endostatin Has ATPase Activity, Which Mediates Its Antiangiogenic and Antitumor Activities
Authors: Wang Shan , Lu Xin-an , Liu Peng , Fu Yan , Jia Lin , Zhan Shunli , Luo Yongzhang
Published: April 2023

Supplementary Figure S5. Tumor photos
Supplementary Figure S2 from Endostatin Has ATPase Activity, Which Mediates Its Antiangiogenic and Antitumor Activities
Authors: Wang Shan , Lu Xin-an , Liu Peng , Fu Yan , Jia Lin , Zhan Shunli , Luo Yongzhang
Published: April 2023

Supplementary Figure S2. Bioluminescent assays
Supplemental Figure Legend and Supplemental Table from MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma
Authors: Slotkin Emily K. , Patwardhan Parag P. , Vasudeva Shyamprasad D. , de Stanchina Elisa , Tap William D. , Schwartz Gary K.
Published: April 2023

Supplemental Figure Legend and Supplemental Table showing list of antibodies used in the study
S2. Formal assessment of AZD5363 combination indices in response to the addition of various endocrine agents. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo
Authors: Ribas Ricardo , Pancholi Sunil , Guest Stephanie K. , Marangoni Elisabetta , Gao Qiong , Thuleau Aurélie , Simigdala Nikiana , Polanska Urszula M. , Campbell Hayley , Rani Aradhana , Liccardi Gianmaria , Johnston Stephen , Davies Barry R. , Dowsett Mitch , Martin Lesley-Ann
Published: April 2023

Cell lines were treated as described with GI50 concentrations of each drug alone or in combination, as indicated in the graphs. For Combination Index Tables shown, each graph cells were treated with AZD5363 and a combination of (A) 4-OHT, (B) fulvestrant and (C) anastrozole over a 6-day period. CIs were derived using Calcusyn software and significance was calculated, as detailed in the Methods.
Supplementary Figure 8 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Supplementary Figure 8 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Supplementary Figure 1 from MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide
Authors: Erice Oihane , Smith Michael P. , White Rachel , Goicoechea Ibai , Barriuso Jorge , Jones Chris , Margison Geoffrey P. , Acosta Juan C. , Wellbrock Claudia , Arozarena Imanol
Published: April 2023

Supplementary Figure 1. A, Colony formation assay 12-well plate layout. B, MGMT promoter methylation assay.
Supplementary Figure Legends and Tables from Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer
Authors: Schlaepfer Isabel R. , Rider Leah , Rodrigues Lindsey Ulkus , Gijón Miguel A. , Pac Colton T. , Romero Lina , Cimic Adela , Sirintrapun S. Joseph , Glodé L. Michael , Eckel Robert H. , Cramer Scott D.
Published: April 2023

Figure legends for supplementary figures and Tables. Supplementary Table 1: Primers used to analyze expression of the ER Stress-related genes and AR-related gene expression. Supplementary Table 2: Antibodies used for immunoblots and IHC.
Sup Figure S1 from The DNA Repair Inhibitor Dbait Is Specific for Malignant Hematologic Cells in Blood
Authors: Thierry Sylvain , Jdey Wael , Alculumbre Solana , Soumelis Vassili , Noguiez-Hellin Patricia , Dutreix Marie
Published: April 2023

Sup Figure S1. AsiDNA Structure and Cell survival in response to AsiDNA treatment. (A) AsiDNA structure: AsiDNA is the clinical form of Dbait, a 64-nucleotide (nt) oligodeoxyribonucleotide consisting of two complementary 32-nt strands, connected through a 1,19-bis(phospho)-8-hydraza-2-hydroxy-4-oxa-9-oxo-nonadecane linker, with a cholesterol at the 5Â'-end and three phosphorothioate internucleotide linkages at each of the 5Â' and the 3Â' ends (Agilent, USA). L is an amino linker, X a cholesteryl tetraethyleneglycol, CL a carboxylic (Hydroxyundecanoic) acid Linker and s a phosphorothioate linkage. (B) Cell survival and cell death in response to AsiDNA treatment: Living cells (white) and dead cells (grey) were measured 4 days after treatment by staining with tyrypan blue and counting cells. Results are expressed as the mean of three to four independent experiments. Error bars represent the standard deviation.
Supplementary Figure 4. Changes in body weight of mice receiving single agent or combination treatment with selinexor or carfilzomib. from Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
Authors: Rosebeck Shaun , Alonge Mattina M. , Kandarpa Malathi , Mayampurath Anoop , Volchenboum Samuel L. , Jasielec Jagoda , Dytfeld Dominik , Maxwell Sean P. , Kraftson Stephanie J. , McCauley Dilara , Shacham Sharon , Kauffman Michael , Jakubowiak Andrzej J.
Published: April 2023

Body weights of all xenografted mice treated with selinexor and carfilzomib, alone and in combination.
supplementary figure 1 from Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma
Authors: Noguchi Fumihito , Inui Shigeki , Fedele Clare , Shackleton Mark , Itami Satoshi
Published: April 2023

Supplementary Figure S1, related to Figure 1. pHe is a threshold that modulates the cytotoxicity of OXPHOSi on melanoma cells in vitro
Supplementary Video S3 from Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform
Authors: Zhang Yilin , Sriraman Shravan Kumar , Kenny Hilary A. , Luther Ed , Torchilin Vladimir , Lengyel Ernst
Published: April 2023

SKOV3-TR treated with LP(XR,PCT)
Supplementary Figure S4. Evaluation of disease state in vehicle control treated animals by IHC. from In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia
Authors: Hagemann Urs B. , Wickstroem Katrine , Wang Ellen , Shea Adam O. , Sponheim Kristine , Karlsson Jenny , Bjerke Roger M. , Ryan Olav B. , Cuthbertson Alan S.
Published: April 2023

Isolated kidneys (A, B) and bone marrow (C, D) were co-stained with a CD33-specific antibody (A, C) and a CD45-specific antibody (B, D).
Sup Figure 8 from Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC
Authors: Potter Danielle S. , Galvin Melanie , Brown Stewart , Lallo Alice , Hodgkinson Cassandra L. , Blackhall Fiona , Morrow Christopher J. , Dive Caroline
Published: April 2023

Supplementary Figure 8. PI3K signaling in CDX2
Sup Figure 7 from Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC
Authors: Potter Danielle S. , Galvin Melanie , Brown Stewart , Lallo Alice , Hodgkinson Cassandra L. , Blackhall Fiona , Morrow Christopher J. , Dive Caroline
Published: April 2023

Supplementary Figure 7. In vivo tolerance study
Sup Figure 6 from Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC
Authors: Potter Danielle S. , Galvin Melanie , Brown Stewart , Lallo Alice , Hodgkinson Cassandra L. , Blackhall Fiona , Morrow Christopher J. , Dive Caroline
Published: April 2023

Supplementary Figure 6. Statistics for knockdown experiments
Supplementary Figure S1 from AKT Inhibition Promotes Nonautonomous Cancer Cell Survival
Authors: Solé Xavier , Alves Cleidson P. , Dey-Guha Ipsita , Ritsma Laila , Boukhali Myriam , Lee Ju H. , Chowdhury Joeeta , Ross Kenneth N. , Haas Wilhelm , Vasudevan Shobha , Ramaswamy Sridhar
Published: April 2023

Changes in RNA Pol II pausing after AKTi treatment
FigureS4 from Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors
Authors: Chanal Marie , Chevallier Pascale , Raverot Véronique , Fonteneau Guillaume , Lucia Kristin , Monteserin Garcia Jose Luis , Rachwan Alexa , Jouanneau Emmanuel , Trouillas Jacqueline , Honnorat Jérôme , Auger Carole , Theodoropoulou Marily , Raverot Gérald
Published: April 2023

Figure S4 Effect of NVP-BEZ235 and NVP-BKM120 treatments on phosphorylated p44/42 MAPK(Thr202/Tyr204) in (A) GH3 cells and (B-C) SMtTW3 tumors. (A) Treatments were performed with DMSO, NVP-BEZ235 or NVP-BKM120 at concentrations 1, 100, and 250 nM for 24 hours. (B,C) Same samples as in Figure 5. The western blot for p44/42 MAPK(Thr202/Tyr204) was followed by blotting for total p44/42 MAPK after stripping in Tris buffer, pH 2.0.
FigureS2 from Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors
Authors: Chanal Marie , Chevallier Pascale , Raverot Véronique , Fonteneau Guillaume , Lucia Kristin , Monteserin Garcia Jose Luis , Rachwan Alexa , Jouanneau Emmanuel , Trouillas Jacqueline , Honnorat Jérôme , Auger Carole , Theodoropoulou Marily , Raverot Gérald
Published: April 2023

Tolerance of NVP-BKM120 treatment on rats. Growth curve (A) or glycemia (B) of rats before and during 4 weeks of NVP-BKM120 treatment 5 mg/kg/d, 5 days a week or control.
FigureS1 from Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors
Authors: Chanal Marie , Chevallier Pascale , Raverot Véronique , Fonteneau Guillaume , Lucia Kristin , Monteserin Garcia Jose Luis , Rachwan Alexa , Jouanneau Emmanuel , Trouillas Jacqueline , Honnorat Jérôme , Auger Carole , Theodoropoulou Marily , Raverot Gérald
Published: April 2023

Tolerance of NVP-BEZ235 treatment on rats. Growth curve of rats before and during 3 weeks (A) or 6 weeks (B) of NVP-BEZ235 treatment 20 mg/kg/d, 5 days a week or control.
suppl. Fig. 2 from PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway
Authors: Engert Florian , Schneider Cornelius , Weiβ Lilly Magdalena , Probst Marie , Fulda Simone
Published: April 2023

Screening for synergistic drug interactions of PARP inhibitors and chemotherapeutic drugs.
Figure S6 from Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues
Authors: Zhu Charles , Bandekar Amey , Sempkowski Michelle , Banerjee Sangeeta Ray , Pomper Martin G. , Bruchertseifer Frank , Morgenstern Alfred , Sofou Stavroula
Published: April 2023

Viability (evaluated after one doubling time) of PSMA-positive HUVEC as a function of delivered radioactivity per cell.
Figure S1 from Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma
Authors: Morgan Katherine M. , Fischer Bruce S. , Lee Francis Y. , Shah Jamie J. , Bertino Joseph R. , Rosenfeld Jeffrey , Singh Amartya , Khiabanian Hossein , Pine Sharon R.
Published: April 2023

Comparison of Notch inhibition between the gamma secretase inhibitors BMS-906024 and RO4929097.
Supplementary Table S1 from Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer
Authors: Gabrielli Brian , Bokhari Fawzi , Ranall Max V. , Oo Zay Yar , Stevenson Alexander J. , Wang Weili , Murrell Melanie , Shaikh Mushfiq , Fallaha Sora , Clarke Daniel , Kelly Madison , Sedelies Karin , Christensen Melinda , McKee Sara , Leggatt Graham , Leo Paul , Skalamera Dubravka , Soyer H. Peter , Gonda Thomas J. , McMillan Nigel A.J.
Published: April 2023

Primary screening daat from kinome siRNA screen
Supplementary Figures S1-S6 from Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439
Authors: Zou Yongkang , Qi Zhi , Guo Weilong , Zhang Liuzhen , Ruscetti Marcus , Shenoy Tanu , Liu Ningshu , Wu Hong
Published: April 2023

Figure S1. Effects of BAY1082439 on cell apoptosis and cell cycle; Figure S2. BAY1082439 is well tolerated in vivo; Figure S3. BAY1082439 treatment impedes prostate tumor invasion; Figure S4. BAY1082439 treatment inhibit CRPC growth in castrated CP mice; Figure S5. B cell infiltration promote CRPC growth in CP model; Figure S6. Effects of BAY1082439 on splenic B cell growth and tumor infiltrating CD8 T cell
Supplementary Figure 7 from mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells
Authors: Koppenhafer Stacia L. , Goss Kelli L. , Terry William W. , Gordon David J.
Published: April 2023

Supplementary Figure 7 shows the effects of gemcitabine on protein synthesis in U2OS and RPE-tert cells.
Supplementary Tables S4, S5 from Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics
Authors: Ember Stuart W. , Lambert Que T. , Berndt Norbert , Gunawan Steven , Ayaz Muhammad , Tauro Marilena , Zhu Jin-Yi , Cranfill Paula J. , Greninger Patricia , Lynch Conor C. , Benes Cyril H. , Lawrence Harshani R. , Reuther Gary W. , Lawrence Nicholas J. , Schönbrunn Ernst
Published: April 2023

Table S4: Kinome profiling data (Microsoft Excel sheet) Table S5: Cell line screening data (Microsoft Excel sheet)
Supplementary Tables S1-S3 and Figures S1-S11 from Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics
Authors: Ember Stuart W. , Lambert Que T. , Berndt Norbert , Gunawan Steven , Ayaz Muhammad , Tauro Marilena , Zhu Jin-Yi , Cranfill Paula J. , Greninger Patricia , Lynch Conor C. , Benes Cyril H. , Lawrence Harshani R. , Reuther Gary W. , Lawrence Nicholas J. , Schönbrunn Ernst
Published: April 2023

Table S1: Crystallographic data collection and refinement statistics Table S2: Inhibitory activity against other BET bromodomains Table S3: Bromodomain profiling data Fig. S1: Detailed binding interactions of compounds 1 - 5 in BRD4-1 Fig. S2: Comparison of compound 2 and JQ1 in Brd4-1 Fig. S3: Chemical structures of other compounds used in this work. Fig. S4: Statistical evaluation of kinome profiling data using the Gini coefficient Fig. S5: Original flow cytometry data of MM1.S cells Fig. S6: MM1.S cells require stimulation with IL-6 to detect phospho-STAT3 levels Fig. S7: Effect of dual BRD4-kinase inhibitors on MV-4-11 cells. Fig. S8: Time dependent alteration of c-Myc and p21Cip1 levels in MM1.S cells. Fig. S9: Effect of dual BET-kinase inhibitors on ruxolitinib sensitive MPN cell lines Fig. S10: Dose-effect analysis of UKE-1 cells treated with drug combinations Fig. S11: Cell line sensitivity by tissue type
figure S8 from A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity
Authors: Vega Mario I. , Shi Yijiang , Frost Patrick , Huerta-Yepez Sara , Antonio-Andres Gabriela , Hernandez-Pando Rogelio , Lee Jihye , Jung Michael E. , Gera Joseph F. , Lichtenstein Alan
Published: April 2023

Supplemental figure 8: Representative sections of liver obtained from control (DMSO) mice or mice injected IP daily with drug 3g at 20mg/kg. Magnification=100x
Table S4 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer
Authors: Hisamatsu Takeshi , McGuire Michael , Wu Sherry Y. , Rupaimoole Rajesha , Pradeep Sunila , Bayraktar Emine , Noh Kyunghee , Hu Wei , Hansen Jean M. , Lyons Yasmin , Gharpure Kshipra M. , Nagaraja Archana S. , Mangala Lingegowda S. , Mitamura Takashi , Rodriguez-Aguayo Cristian , Eun Young Gyu , Rose Johnathon , Bartholomeusz Geoffrey , Ivan Cristina , Lee Ju-Seog , Matsuo Koji , Frumovitz Michael , Wong Kwong K. , Lopez-Berestein Gabriel , Sood Anil K.
Published: April 2023

Kinome screen data
Supplementary Figure S6. from Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer
Authors: Singh Krishna B. , Ji Xinhua , Singh Shivendra V.
Published: April 2023

Densitometric quantitation of AR protein expression in 22Rv1 and LNCaP cells (for data shown in Fig. 3B of the main text) after treatment with MG132 and/or LLM.
Supplementary Tables S16-S20 from A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics
Authors: Quist Jelmar , Mirza Hasan , Cheang Maggie C.U. , Telli Melinda L. , O'Shaughnessy Joyce A. , Lord Christopher J. , Tutt Andrew N.J. , Grigoriadis Anita
Published: April 2023

Supplementary Table S16: Results from the gene set enrichment analysis of 28 different immune signatures across the METABRIC-set 15 (MC subtypes) classification. Supplementary Table S17: Table representing the copy number status of the five genes part of the MAPK inactivation score across the METABRIC-set 15 (MC subtypes) classification. Supplementary Table S18: Output of the multivariable logistic regression analysis for the MC6 and the BL1 subtype in Sanofi Phase II. Supplementary Table S19: Output of the multivariable logistic regression analysis for the MC6 and the BL1 subtype in Sanofi Phase III. Supplementary Table S20: Results from the drug screen performed between MC6 and non-MC6 TNBC cell lines.
Figure S4 from Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer
Authors: Xu Sen , Yang Zongyuan , Jin Ping , Yang Xin , Li Xiaoting , Wei Xiao , Wang Ya , Long Sixiang , Zhang Taoran , Chen Gang , Sun Chaoyang , Ma Ding , Gao Qinglei
Published: April 2023

Effect of reported STAT3 inhibitors on STAT3 signaling of SKOV3, related to Figure 5.
Supplementary Figure 4 from The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models
Authors: Handle Florian , Puhr Martin , Schaefer Georg , Lorito Nicla , Hoefer Julia , Gruber Martina , Guggenberger Fabian , Santer Frédéric R. , Marques Rute B. , van Weerden Wytske M. , Claessens Frank , Erb Holger H.H. , Culig Zoran
Published: April 2023

Response to galiellalactone is not determined by the basal expression level
Supplementary Figure 3 from The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models
Authors: Handle Florian , Puhr Martin , Schaefer Georg , Lorito Nicla , Hoefer Julia , Gruber Martina , Guggenberger Fabian , Santer Frédéric R. , Marques Rute B. , van Weerden Wytske M. , Claessens Frank , Erb Holger H.H. , Culig Zoran
Published: April 2023

The GR is expressed in some of the used cell lines
Figures S1-S6 from Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy
Authors: Zheng Lin , Chen Zibo , Kawakami Masanori , Chen Yulong , Roszik Jason , Mustachio Lisa Maria , Kurie Jonathan M. , Villalobos Pamela , Lu Wei , Behrens Carmen , Mino Barbara , Solis Luisa M. , Silvester Jennifer , Thu Kelsie L. , Cescon David W , Rodriguez-Canales Jaime , Wistuba Ignacio I. , Mak Tak W. , Liu Xi , Dmitrovsky Ethan
Published: April 2023

Figure S1: The structure of CFI-402257. Figure S2: TTK mRNA expression profiles in lung cancer cases with different smoking patterns, as shown in panel A. In this left panel N means no smoking history while Y indicates the presence of a smoking history. That was displayed in the right panel as never, former or current smokers. Panel B displays the anti-proliferative effects of CFI-402257 relative to vehicle treatments in lung adenocarcinoma cell lines. The area under the curve was calculated based on the proportion of control values and log10 dosage values to generate dose-response curves. Error bars are standard deviations. Figure S3: Immunoblot analysis of ED1 (A) and A549 (B) lung cancer cells after independent transfection with TTK-targeting (siRNA1 and siRNA2) or control siRNAs. Figure S4: Representative photomicrographs of 393P (A) or H1299 (B) lung cancer cell line-derived tumors after 21 days of CFI-402257 or vehicle treatments. (C) Syngeneic 393P tumor-bearing mice were treated with vehicle, 8.5 mg/kg CFI-402257 orally for 5 days, after which tumors were harvested for RPPA analyses (n = 5 mice per group). Comparison of the 8.5mg/kg CFI-402257-treated group to vehicle-treated groups. The proteins displayed above the red line are significantly different (P < 0.05). Figure S5: (A) The association between survival and expression of MAP2K1/MAP2K2 and TTK in combination using TCGA. Green: MAP2K low/TTK low, purple: MAP2K low/TTK high, orange: MAP2K high/TTK low and red: MAP2K high/TTK high. (B) The combination index (CI) for each dosage pair was calculated. The dash line indicates CI=1.0. Figure S6: TTK mutations in lung adenocarcinomas (A) and squamous cell carcinomas (B) in TCGA database.
Table S2 from Metabolite Profiling Reveals the Glutathione Biosynthetic Pathway as a Therapeutic Target in Triple-Negative Breast Cancer
Authors: Beatty Alexander , Fink Lauren S. , Singh Tanu , Strigun Alexander , Peter Erik , Ferrer Christina M. , Nicolas Emmanuelle , Cai Kathy Q. , Moran Timothy P. , Reginato Mauricio J. , Rennefahrt Ulrike , Peterson Jeffrey R.
Published: April 2023

Table S2. Principal component analysis loadings for plots shown in Figure 1C and Figure 1D, included as separate Excel file.
Table S1 from Metabolite Profiling Reveals the Glutathione Biosynthetic Pathway as a Therapeutic Target in Triple-Negative Breast Cancer
Authors: Beatty Alexander , Fink Lauren S. , Singh Tanu , Strigun Alexander , Peter Erik , Ferrer Christina M. , Nicolas Emmanuelle , Cai Kathy Q. , Moran Timothy P. , Reginato Mauricio J. , Rennefahrt Ulrike , Peterson Jeffrey R.
Published: April 2023

Table S1. Culturing conditions for cell lines and primary cells, related to Experimental Procedures.
Supplementary figures from Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
Authors: Delpuech Oona , Rooney Claire , Mooney Lorraine , Baker Dawn , Shaw Robert , Dymond Michael , Wang Dennis , Zhang Pei , Cross Sarah , Veldman-Jones Margaret , Wilson Joanne , Davies Barry R. , Dry Jonathan R. , Kilgour Elaine , Smith Paul D.
Published: April 2023

Supplementary figures S1: volcano plot of insensitive cell lines treated by AZD4547 S2:Immunohistochemistry of p-S6 and p-ERK tissue sections from xenograft treated with AZD4547 S3:FGFR pathway modulation in xenograft models treated with AZD4547 S4: ANC3A xenograft tumour growth inhibition after treated with AZD4547 and/or AZD5363 S5: AZD4547 dynamic biomarkers in ANC3A model after 14 days treatment with AKT and FGFR inhibitors
Supplementary Materials and Methods from TGFβ-induced SMAD4-dependent Apoptosis Proceeded by EMT in CRC
Authors: Siraj Abdul K. , Pratheeshkumar Poyil , Divya Sasidharan Padmaja , Parvathareddy Sandeep Kumar , Bu Rong , Masoodi Tariq , Kong Yan , Thangavel Saravanan , Al-Sanea Nasser , Ashari Luai H. , Abduljabbar Alaa , Al-Homoud Samar , Al-Dayel Fouad , Al-Kuraya Khawla S.
Published: April 2023

Supplementary Materials and Methods
Information about supplementary Tables from Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cell–Like Phenotype
Authors: Bian Yansong , Teper Yaroslav , Mathews Griner Lesley A. , Aiken Taylor J. , Shukla Vivek , Guha Rajarshi , Shinn Paul , Xin Hong-Wu , Pflicke Holger , Powers Astin S. , Li Dandan , Jiang Jian-kang , Patel Paresma , Rogers Steven A. , Aubé Jeffrey , Ferrer Marc , Thomas Craig J. , Rudloff Udo
Published: April 2023

Suppl. Table 1. Origin of cancer cell lines used in this study. Suppl. Table 2. Quantitative HTS screen in PANC1 cells grown as spheroids. Results of full ten concentration drug-response curves of 1,912 individual agents and compounds in PANC1 spheroids. SID, Sample ID; CCLASS, Curve class; CCLASS2, Curve class (latest version); LAC50, log AC50 (M); HILL, Hill coefficient; ZERO, fitted response at minimum concentration; INF, Fitted response at maximum concentration; MAXR, Observed response at maximum concentration; DATA0 - DATA10, Responses; C0 - C10, Doses (in ÂµM); auc, Area Under the Curve (via integration of the fit). This data is available via the PubChem database (AID 1259363). Suppl. Table 3 Top twenty hits of KiNativ profiling of PANC1 cells with at least {greater than or equal to}50 percent inhibition of ADP binding following treatment with 500 nM of inhibitor #1. Suppl. Table 4. In vitro activity of inhibitor #1 against a panel of over 400 kinases (DiscoveRx's KinomeScan) and in situ activity of inhibitor #1 in PANC1 spheroid cells (KiNative). Suppl. Table 5. Outcomes of both 6Ã-6 and 10Ã-10 combination drug screening of inhibitor #1 versus a collection of approved and investigational drugs.
Supplementary Table S1 from Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma
Authors: Yu Yang , Zhao Yanling , Fan Yihui , Chen Zhenghu , Li Hui , Lu Jiaxiong , Guo Kevin , Woodfield Sarah E. , Vasudevan Sanjeev A. , Yang Jianhua , Nuchtern Jed G.
Published: April 2023

Summary of 6 neuroblastoma cell lines
Supplementary Figure S4 from Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma
Authors: Yu Yang , Zhao Yanling , Fan Yihui , Chen Zhenghu , Li Hui , Lu Jiaxiong , Guo Kevin , Woodfield Sarah E. , Vasudevan Sanjeev A. , Yang Jianhua , Nuchtern Jed G.
Published: April 2023

USP14 inhibitor b-AP15 enhances Doxorubicin- and VP-16-induced cytotoxicity in neuroblastoma cells.
Supplementary Figure S4 from A Novel Inhibitor of AKT1–PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo
Authors: Mäemets-Allas Kristina , Viil Janeli , Jaks Viljar
Published: April 2023

Luminescent cell viability assay
Supplementary Figure S2 from Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma
Authors: Yu Yang , Zhao Yanling , Fan Yihui , Chen Zhenghu , Li Hui , Lu Jiaxiong , Guo Kevin , Woodfield Sarah E. , Vasudevan Sanjeev A. , Yang Jianhua , Nuchtern Jed G.
Published: April 2023

The effect of USP14 knockdown on NB cell cycle distributions.
Supplementary Figure S2 from A Novel Inhibitor of AKT1–PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo
Authors: Mäemets-Allas Kristina , Viil Janeli , Jaks Viljar
Published: April 2023

NSC156529 inhibited the AKT1-PDPK1 interaction
Supplementary Figure S8 from Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis
Authors: Kenny Hilary A. , Lal-Nag Madhu , Shen Min , Kara Betul , Nahotko Dominik A. , Wroblewski Kristen , Fazal Sarah , Chen Siquan , Chiang Chun-Yi , Chen Yen-Ju , Brimacombe Kyle R. , Marugan Juan , Ferrer Marc , Lengyel Ernst
Published: April 2023

Supplementary Figure S8 shows the validation of gene regulation by NCGC00117362 in ovarian cancer cell lines and effect of PP-121 and Milciclib on these genes.
Supplementary Figure S7 from Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis
Authors: Kenny Hilary A. , Lal-Nag Madhu , Shen Min , Kara Betul , Nahotko Dominik A. , Wroblewski Kristen , Fazal Sarah , Chen Siquan , Chiang Chun-Yi , Chen Yen-Ju , Brimacombe Kyle R. , Marugan Juan , Ferrer Marc , Lengyel Ernst
Published: April 2023

Supplementary Figure S7 shows the effect of Milciclib and NCGC00117362 on mTOR, and PP-121 and NCGC00117362 on retinoblastoma.
Supplementary Figure S6 from Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis
Authors: Kenny Hilary A. , Lal-Nag Madhu , Shen Min , Kara Betul , Nahotko Dominik A. , Wroblewski Kristen , Fazal Sarah , Chen Siquan , Chiang Chun-Yi , Chen Yen-Ju , Brimacombe Kyle R. , Marugan Juan , Ferrer Marc , Lengyel Ernst
Published: April 2023

Supplementary Figure S6 shows the effect of Milciclib on cyclin E low- and high-expressing ovarian cancer cell lines.
Supplementary Figure S1 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
Authors: Sidarovich Viktoryia , De Mariano Marilena , Aveic Sanja , Pancher Michael , Adami Valentina , Gatto Pamela , Pizzini Silvia , Pasini Luigi , Croce Michela , Parodi Federica , Cimmino Flora , Avitabile Marianna , Emionite Laura , Cilli Michele , Ferrini Silvano , Pagano Aldo , Capasso Mario , Quattrone Alessandro , Tonini Gian Paolo , Longo Luca
Published: April 2023

Validation of candidate FDA-approved drugs.
Supplemental Figure S2 from Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis
Authors: Kenny Hilary A. , Lal-Nag Madhu , Shen Min , Kara Betul , Nahotko Dominik A. , Wroblewski Kristen , Fazal Sarah , Chen Siquan , Chiang Chun-Yi , Chen Yen-Ju , Brimacombe Kyle R. , Marugan Juan , Ferrer Marc , Lengyel Ernst
Published: April 2023

Supplementary Figure S2 shows the activity outcomes from confirmatory and counter screens.
Supplementary Fig. S3 from A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical–Genetic High-Content Phenotypic Screen
Authors: Dawson John C. , Serrels Bryan , Byron Adam , Muir Morwenna T. , Makda Ashraff , García-Muñoz Amaya , von Kriegsheim Alex , Lietha Daniel , Carragher Neil O. , Frame Margaret C.
Published: April 2023

Analysis of HDAC and FAK inhibition across a panel of 35 human cell lines.
Supplementary Methods from EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer
Authors: Viswanadhapalli Suryavathi , Luo Yiliao , Sareddy Gangadhara R. , Santhamma Bindu , Zhou Mei , Li Mengxing , Ma Shihong , Sonavane Rajni , Pratap Uday P. , Altwegg Kristin A. , Li Xiaonan , Chang Annabel , Chávez-Riveros Alejandra , Dileep Kalarickal V. , Zhang Kam Y.J. , Pan Xinlei , Murali Ramachandran , Bajda Marek , Raj Ganesh V. , Brenner Andrew J. , Manthati Vijaya , Rao Manjeet K. , Tekmal Rajeshwar R. , Nair Hareesh B. , Nickisch Klaus J. , Vadlamudi Ratna K.
Published: April 2023

Supplementary methods section contain description of synthesis and characterization of EC330 and EC359, SPR studies, structural and sequence comparison of human and mouse LIFR, energy minimization of hLIFR, Protein and ligand preparation, molecular docking and MM-GBSA calculations, and molecular dynamics simulation.
Supplementary figures 1-2 from Preclinical Development of a WT1 Oral Cancer Vaccine Using a Bacterial Vector to Treat Castration-Resistant Prostate Cancer
Authors: Kitagawa Koichi , Gonoi Reina , Tatsumi Maho , Kadowaki Masahide , Katayama Takane , Hashii Yoshiko , Fujisawa Masato , Shirakawa Toshiro
Published: April 2023

Supplementary Fig. S1. Representative dot blots of Intracellular cytokine staining (ICCS) in Figure 1B. After vaccination, mice splenocytes were obtained and re-stimulated with TRAMP-C2 in vitro. ICCS was performed for IFN-γ, IL-2 and TNF-α-producing CD4T and CD8T cells. Splenocytes were gated by front scatter (FSC) and side scatter (SSC). After gating with CD3, splenocytes were separated CD4T and CD8T that were producing each cytokine. Representative dot plots were shown in this figure. Supplementary Fig. S2. Representative dot plots of Intracellular cytokine staining (ICCS) of the significant data in Figure 4. After vaccination, mice splenocytes were obtained and re-stimulated with following peptides; Db126, WH187, mp235, Db332 and A24 in vitro. ICCS was performed for IFN-γ, IL-2 and TNF-α-producing CD4T and CD8T cells. Splenocytes were gated by front scatter (FSC) and side scatter (SSC). After gating with CD3, splenocytes were separated CD4T and CD8T that were producing each cytokine. Representative dot plots of the significant data were shown in this figure.
Supplementary Table S2 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
Authors: Hudson Kevin , Hancox Urs J. , Trigwell Cath , McEwen Robert , Polanska Urszula M. , Nikolaou Myria , Morentin Gutierrez Pablo , Avivar-Valderas Alvaro , Delpuech Oona , Dudley Phillippa , Hanson Lyndsey , Ellston Rebecca , Jones Alys , Cumberbatch Marie , Cosulich Sabina C. , Ward Lara , Cruzalegui Francisco , Green Stephen
Published: April 2023

Tumor cell line panel composition and growth inhibition sensitivity (GI50) to AZD8835.
Supplementary File S1 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
Authors: Hudson Kevin , Hancox Urs J. , Trigwell Cath , McEwen Robert , Polanska Urszula M. , Nikolaou Myria , Morentin Gutierrez Pablo , Avivar-Valderas Alvaro , Delpuech Oona , Dudley Phillippa , Hanson Lyndsey , Ellston Rebecca , Jones Alys , Cumberbatch Marie , Cosulich Sabina C. , Ward Lara , Cruzalegui Francisco , Green Stephen
Published: April 2023

Contains Supplementary Material and Methods, Suuplementary Table & Figure Legends and Supplementary References.
Supplementary Figure S7 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
Authors: Hudson Kevin , Hancox Urs J. , Trigwell Cath , McEwen Robert , Polanska Urszula M. , Nikolaou Myria , Morentin Gutierrez Pablo , Avivar-Valderas Alvaro , Delpuech Oona , Dudley Phillippa , Hanson Lyndsey , Ellston Rebecca , Jones Alys , Cumberbatch Marie , Cosulich Sabina C. , Ward Lara , Cruzalegui Francisco , Green Stephen
Published: April 2023

Body Weight time-courses for AZD8835 combination efficacy studies.
Supplementary Figure S6 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
Authors: Hudson Kevin , Hancox Urs J. , Trigwell Cath , McEwen Robert , Polanska Urszula M. , Nikolaou Myria , Morentin Gutierrez Pablo , Avivar-Valderas Alvaro , Delpuech Oona , Dudley Phillippa , Hanson Lyndsey , Ellston Rebecca , Jones Alys , Cumberbatch Marie , Cosulich Sabina C. , Ward Lara , Cruzalegui Francisco , Green Stephen
Published: April 2023

Combination of AZD8835 with mTOR kinase inhibitor AZD2014 (+/- fulvestrant) increases anti-tumor efficacy in breast xenografts
Supplementary Figure S5 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
Authors: Hudson Kevin , Hancox Urs J. , Trigwell Cath , McEwen Robert , Polanska Urszula M. , Nikolaou Myria , Morentin Gutierrez Pablo , Avivar-Valderas Alvaro , Delpuech Oona , Dudley Phillippa , Hanson Lyndsey , Ellston Rebecca , Jones Alys , Cumberbatch Marie , Cosulich Sabina C. , Ward Lara , Cruzalegui Francisco , Green Stephen
Published: April 2023

AZD8835 combination with SERDs (fulvestrant or AZD9496) results in tumor regression in mutant PIK3CA, ER+ breast xenografts.
Supplementary Figure S4 from Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
Authors: Hudson Kevin , Hancox Urs J. , Trigwell Cath , McEwen Robert , Polanska Urszula M. , Nikolaou Myria , Morentin Gutierrez Pablo , Avivar-Valderas Alvaro , Delpuech Oona , Dudley Phillippa , Hanson Lyndsey , Ellston Rebecca , Jones Alys , Cumberbatch Marie , Cosulich Sabina C. , Ward Lara , Cruzalegui Francisco , Green Stephen
Published: April 2023

Proliferation and mechansitic assays in mutant PIK3CA, ER+ breast cell lines studying combinations of AZD8835 with SERDs, palbociclib or AZD2014.
Supplementary Table S1 from MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers
Authors: Fricke Stephanie L. , Payne Susan N. , Favreau Peter F. , Kratz Jeremy D. , Pasch Cheri A. , Foley Tyler M. , Yueh Alexander E. , Van De Hey Dana R. , Depke Mitchell G. , Korkos Demetra P. , Sha Gioia Chengcheng , DeStefanis Rebecca A. , Clipson Linda , Burkard Mark E. , Lemmon Kayla K. , Parsons Benjamin M. , Kenny Paraic A. , Matkowskyj Kristina A. , Newton Michael A. , Skala Melissa C. , Deming Dustin A.
Published: April 2023

Supplementary Table S1 compares the intestinal tumor counts and percent of tumors progressing to cancer for mouse models with activating alterations in PIK3CA.
Supplementary Figure S3 from Inhibition of Heparanase in Pediatric Brain Tumor Cells Attenuates their Proliferation, Invasive Capacity, and In Vivo Tumor Growth
Authors: Spyrou Argyris , Kundu Soumi , Haseeb Lulu , Yu Di , Olofsson Tommie , Dredge Keith , Hammond Edward , Barash Uri , Vlodavsky Israel , Forsberg-Nilsson Karin
Published: April 2023

PG545 does not pass the blood-brain barrier (BBB), reduces flank tumor weight in mice, and causes no weight loss
Supplementary Figure Legends from Inhibition of Heparanase in Pediatric Brain Tumor Cells Attenuates their Proliferation, Invasive Capacity, and In Vivo Tumor Growth
Authors: Spyrou Argyris , Kundu Soumi , Haseeb Lulu , Yu Di , Olofsson Tommie , Dredge Keith , Hammond Edward , Barash Uri , Vlodavsky Israel , Forsberg-Nilsson Karin
Published: April 2023

Supplementary Figure Legends
Supplementary Figure S3 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Authors: Totiger Tulasigeri M. , Srinivasan Supriya , Jala Venkatakrishna R. , Lamichhane Purushottam , Dosch Austin R. , Gaidarski Alexander A. , Joshi Chandrashekhar , Rangappa Shobith , Castellanos Jason , Vemula Praveen Kumar , Chen Xi , Kwon Deukwoo , Kashikar Nilesh , VanSaun Michael , Merchant Nipun B. , Nagathihalli Nagaraj S.
Published: April 2023

Supplementary Figure S3 shows PhosphoKinase array analysis in MiaPaCa2 cells treated with Uro A.
Figures S1-S4 and Supplementary Methods from Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells
Authors: Fuse Marisa A. , Plati Stephani Klingeman , Burns Sarah S. , Dinh Christine T. , Bracho Olena , Yan Denise , Mittal Rahul , Shen Rulong , Soulakova Julia N. , Copik Alicja J. , Liu Xue Zhong , Telischi Fred F. , Chang Long-Sheng , Franco Maria Clara , Fernandez-Valle Cristina
Published: April 2023

All supplementary data - four figures and supplementary methods
Supplementary Table 5 from A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity
Authors: Hu Sophia , Ueda Masumi , Stetson Lindsay , Ignatz-Hoover James , Moreton Stephen , Chakrabarti Amit , Xia Zhiqiang , Karan Goutam , de Lima Marcos , Agrawal Mukesh K. , Wald David N.
Published: April 2023

Microarray pathway analysis
Table S1, Figure S1, Figure S2, Figure S3 from mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment
Authors: Orr-Asman Melissa A. , Chu Zhengtao , Jiang Min , Worley Mariah , LaSance Kathleen , Koch Sheryl E. , Carreira Vinicius S. , Dahche Hanan M. , Plas David R. , Komurov Kakajan , Qi Xiaoyang , Mercer Carol A. , Anthony Lowell B. , Rubinstein Jack , Thomas Hala E.
Published: April 2023

Table S1. CC-223-treated mice tend to develop less histopathologic lesions of the heart valves than either rapamycin- or placebo-treated mice. Figure S1. MLN0128 inhibited mTOR signaling in human pNET cell lines in a dose-dependent manner. Figure S2. Mean tumor volumes of rapamycin, CC-223 responders and non-responders over time. Figure S3. Tumor burden, DDC and/or serum serotonin levels in nude mice either orthotopically or subcutaneously injected with BON-luci cells and treated with placebo, rapamycin or CC-223.
Supplementary Figure 5 from A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity
Authors: Hu Sophia , Ueda Masumi , Stetson Lindsay , Ignatz-Hoover James , Moreton Stephen , Chakrabarti Amit , Xia Zhiqiang , Karan Goutam , de Lima Marcos , Agrawal Mukesh K. , Wald David N.
Published: April 2023

Heatmap of Z-scores of genes that are significantly dysregulated
Supplementary figure S3 from Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism
Authors: Wiedmer Tabea , Blank Annika , Pantasis Sophia , Normand Lea , Bill Ruben , Krebs Philippe , Tschan Mario P. , Marinoni Ilaria , Perren Aurel
Published: April 2023

Effect of sunitinib on viability and cell cycle of PanNET cell lines and expression of its target receptors
Supplementary Figure 1 from A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity
Authors: Hu Sophia , Ueda Masumi , Stetson Lindsay , Ignatz-Hoover James , Moreton Stephen , Chakrabarti Amit , Xia Zhiqiang , Karan Goutam , de Lima Marcos , Agrawal Mukesh K. , Wald David N.
Published: April 2023

GS87 does not significantly impact the viability of AML cells
Supplemental Figure 6 from Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
Authors: Datta Jharna , Damodaran Senthilkumar , Parks Hannah , Ocrainiciuc Cristina , Miya Jharna , Yu Lianbo , Gardner Elijah P. , Samorodnitsky Eric , Wing Michele R. , Bhatt Darshna , Hays John , Reeser Julie W. , Roychowdhury Sameek
Published: April 2023

MAPK signaling pathway in BGJ398 resistant cell lines.
Supplemental Figure 5 from Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
Authors: Datta Jharna , Damodaran Senthilkumar , Parks Hannah , Ocrainiciuc Cristina , Miya Jharna , Yu Lianbo , Gardner Elijah P. , Samorodnitsky Eric , Wing Michele R. , Bhatt Darshna , Hays John , Reeser Julie W. , Roychowdhury Sameek
Published: April 2023

Principal component analysis of RPPA data for control and resistant cell lines.
Figure S4 from The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells
Authors: Murone Maximilien , Radpour Ramin , Attinger Antoine , Chessex Anne Vaslin , Huguenin Anne-Laure , Schürch Christian M. , Banz Yara , Sengupta Saumitra , Aguet Michel , Rigotti Stefania , Bachhav Yogeshwar , Massière Frédéric , Ramachandra Murali , McAllister Andres , Riether Carsten
Published: April 2023

Figure S4 shows the pharmacokinetics/pharmacodynamics (PK/PD) of Debio 0617B in the rat MV-4-11 AML model.
Supplementary Table 1 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo
Authors: Staudacher Alexander H. , Li Yanrui , Liapis Vasilios , Hou Jeff Jia Cheng , Chin David , Dolezal Olan , Adams Timothy E. , van Berkel Patrick H. , Brown Michael P.
Published: April 2023

Antibody drug conjugates used in the study.
Supplementary Figure 7 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo
Authors: Staudacher Alexander H. , Li Yanrui , Liapis Vasilios , Hou Jeff Jia Cheng , Chin David , Dolezal Olan , Adams Timothy E. , van Berkel Patrick H. , Brown Michael P.
Published: April 2023

Dose escalation study of chDAB4-SG3249 alone or in combination with chemotherapy in LL2 tumor model.
Supplementary Figure 6 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo
Authors: Staudacher Alexander H. , Li Yanrui , Liapis Vasilios , Hou Jeff Jia Cheng , Chin David , Dolezal Olan , Adams Timothy E. , van Berkel Patrick H. , Brown Michael P.
Published: April 2023

DAB4-ADCs with cleavable, but not non-cleavable linkers, are effective in vivo.
Supplementary Figure 5 from APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo
Authors: Staudacher Alexander H. , Li Yanrui , Liapis Vasilios , Hou Jeff Jia Cheng , Chin David , Dolezal Olan , Adams Timothy E. , van Berkel Patrick H. , Brown Michael P.
Published: April 2023

Survival curves for mice treated with DAB4 or chDAB4 antibody drug conjugates.
Supplementary Data from A Combination of BRD4 and HDAC3 Inhibitors Synergistically Suppresses Glioma Stem Cell Growth by Blocking GLI1/IL6/STAT3 Signaling Axis
Authors: Wang Qian , Jia Shengnan , Wang Ding , Chen Xuyang , Kalvakolanu Dhan V. , Zheng Hongwu , Wei Xiaodong , Wen Naiyan , Liang Hang , Guo Baofeng , Zhang Ling
Published: April 2023

Supplementary Data and supplementary figures
Figure S1 from Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes In Vitro and In Vivo: Preclinical Studies as Guidance for Clinical Development and Trial Design
Authors: Sootome Hiroshi , Miura Akihiro , Masuko Norio , Suzuki Takamasa , Uto Yoshihiro , Hirai Hiroshi
Published: April 2023

(a) Structure of TAS-119. (b) IC50 value for each recombinant Aurora kinase.
Supplementary Methods from RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity
Authors: Wang Hong , Ashton Reading , Hensel Jonathan A. , Lee Joo Hyoung , Khattar Vinayak , Wang Yong , Deshane Jessy S. , Ponnazhagan Selvarangan
Published: April 2023

Supplementary Methods
Supplementary Figures from RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity
Authors: Wang Hong , Ashton Reading , Hensel Jonathan A. , Lee Joo Hyoung , Khattar Vinayak , Wang Yong , Deshane Jessy S. , Ponnazhagan Selvarangan
Published: April 2023

Supplementary Figures S1-S6
Supplementary Data from Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
Authors: Anderson Mark G. , Falls Hugh D. , Mitten Michael J. , Oleksijew Anatol , Vaidya Kedar S. , Boghaert Erwin R. , Gao Wenqing , Palma Joann P. , Cao Diana , Chia Puey-Ling , John Thomas , Gan Hui K. , Scott Andrew M. , Reilly Edward B.
Published: April 2023

In vivo Efficacy of ABBV-321 tumor targeting.